Targeting histone modifiers in bladder cancer therapy - preclinical and clinical evidence

Area of Science:

• Oncology
• Epigenetics
• Cancer Biology

Background:

• Muscle-invasive bladder cancer (MIBC) has limited therapeutic advances, with cisplatin-based chemotherapy as the current standard.
• Chromatin remodelling gene mutations are frequent in urothelial bladder carcinoma, presenting novel therapeutic targets.
• Histone modifiers play crucial roles in cancer progression by regulating oncogenes and tumor suppressors.

Purpose of the Study:

• To explore the therapeutic potential of targeting histone modifiers in bladder cancer.
• To review the current understanding of epigenetic reprogramming in bladder cancer progression and drug resistance.
• To assess the efficacy and challenges of epigenetic drugs in clinical settings for bladder cancer.

Main Methods:

• Review of recent advancements in next-generation sequencing for characterizing chromatin remodelling gene mutations.
• Analysis of preclinical studies evaluating the efficacy of targeting histone modifiers genetically or chemically.
• Examination of clinical trial outcomes for epigenetic drugs in advanced bladder cancer.

Main Results:

• Preclinical studies show promise for targeting histone modifiers in bladder cancer.
• Clinical trials investigating these epigenetic drugs have yielded mixed results.
• Alterations in histone modifications are increasingly recognized for their role in bladder cancer progression and drug resistance.

Conclusions:

• Targeting histone modifiers represents a promising avenue for bladder cancer therapy.
• Further research is needed to elucidate the mechanistic roles of histone modifications in bladder cancer.
• Understanding these mechanisms is crucial for the successful clinical application of epigenetic drugs in bladder cancer treatment.